Long-term results back FemSoft urinary insert:
This article was originally published in Clinica
A one to two year follow-up study from an ongoing trial of Rochester Medical's FemSoft female, single-use stress urinary incontinence device has produced positive results. Interim data from the five year, 150-patient trial indicate a statistically significant reduction in both incontinence episodes and amount of urine loss in patients using the FDA-approved FemSoft insert, notes the Stewartville, Minnesota firm. Notably, some 81% of patients reported that they never or rarely experienced incontinence while using the device. The findings appear in the International Urogynecology Journal (May).
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.